Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FOXO Technologies Inc. (FOXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: FOXO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.53% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.99M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.25 | 52 Weeks Range 0.17 - 13.00 | Updated Date 06/28/2025 |
52 Weeks Range 0.17 - 13.00 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.25 |
Earnings Date
Report Date 2025-06-26 | When After Market | Estimate - | Actual -0.368 |
Profitability
Profit Margin -159.67% | Operating Margin (TTM) -48.8% |
Management Effectiveness
Return on Assets (TTM) -17.5% | Return on Equity (TTM) -1754.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11925576 | Price to Sales(TTM) 0.28 |
Enterprise Value 11925576 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 10620600 | Shares Floating 6482011 |
Shares Outstanding 10620600 | Shares Floating 6482011 | ||
Percent Insiders 2.19 | Percent Institutions 0.47 |
Upturn AI SWOT
FOXO Technologies Inc.
Company Overview
History and Background
FOXO Technologies Inc. was founded in 2021, focusing on leveraging epigenetic technology to assess human health and longevity. They aim to commercialize products and services related to life insurance, diagnostics, and wellness.
Core Business Areas
- Life Insurance: Develops and offers life insurance products that are priced based on an individual's epigenetic risk assessment, using FOXO's proprietary technology.
- Diagnostics: Develops diagnostic tests based on epigenetic biomarkers for early disease detection and health risk assessment.
- Wellness: Offers wellness programs and products tailored to individual epigenetic profiles, aimed at promoting longevity and healthy aging.
Leadership and Structure
The leadership team includes Jon Sabes (CEO) and Dr. Brian Chen (Chief Science Officer). The company operates with a focus on research and development, product commercialization, and strategic partnerships.
Top Products and Market Share
Key Offerings
- FOXO Life Insurance: A life insurance product that utilizes epigenetic data to determine premiums and coverage. Market share is currently developing. Competitors include traditional life insurance companies like Prudential Financial (PRU), MetLife (MET), and New York Life.
- FOXO Diagnostic Tests (Development Stage): Diagnostic tests designed to assess biological age and risk for age-related diseases. Currently in development and does not yet have market share. Competitors in this space include companies developing aging and diagnostic tests such as Elysium Health (privately held) and Tally Health (privately held).
- FOXO Wellness Programs (Development Stage): Personalized wellness programs informed by epigenetic data. Currently in development and has no market share. The wellness market is vast and includes many general wellness companies.
Market Dynamics
Industry Overview
The biotechnology sector, particularly focusing on longevity and preventative healthcare, is experiencing significant growth. Advancements in genomics and epigenetics are driving innovation and investment.
Positioning
FOXO Technologies Inc. is positioned as a leader in epigenetic-based health assessment and life insurance, aiming to disrupt traditional underwriting and healthcare approaches. Competitive advantages lie in its proprietary epigenetic technology and data analysis capabilities.
Total Addressable Market (TAM)
The total addressable market for longevity and preventative healthcare is estimated to be in the hundreds of billions of dollars globally. FOXO Technologies Inc. aims to capture a portion of this market through its innovative products and services.
Upturn SWOT Analysis
Strengths
- Proprietary epigenetic technology
- Focus on longevity and preventive healthcare
- Potential to disrupt traditional life insurance underwriting
- Experienced leadership team
Weaknesses
- Relatively new company with limited operating history
- Reliance on successful development and commercialization of products
- Potential regulatory hurdles for epigenetic-based insurance products
- Limited market share and brand recognition
Opportunities
- Expanding the application of epigenetic technology to other areas of healthcare
- Forming strategic partnerships with insurance companies and healthcare providers
- Increasing consumer awareness of epigenetic testing and personalized medicine
- Entering new geographic markets
Threats
- Competition from established life insurance companies and biotechnology firms
- Uncertainty regarding the long-term validity and reliability of epigenetic biomarkers
- Changing regulatory landscape for genetic testing and insurance
- Economic downturn impacting consumer spending on wellness and preventive healthcare
Competitors and Market Share
Key Competitors
- PRU
- MET
- ATH
Competitive Landscape
FOXO faces competition from established insurance providers with extensive distribution networks and brand recognition. FOXO's advantage lies in its innovative use of epigenetics, but it needs to establish credibility and scale its operations. Market shares based on total life insurance market. The company is too new to measure diagnostic or wellness competitive market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent inception. However, initial growth potential looks good.
Future Projections: Future growth projections are based on successful product commercialization and market adoption. Analyst estimates vary.
Recent Initiatives: Recent initiatives include securing patents for its epigenetic technology, developing partnerships for product distribution, and raising capital through public offerings.
Summary
FOXO Technologies is an early-stage company focusing on epigenetic technology for life insurance and healthcare. While its innovative approach offers significant potential, it faces considerable execution risks and competition from established players. Its success depends on product commercialization, regulatory approvals, and market acceptance of epigenetic testing. The company is a high-risk, high-reward investment, needing to capitalize on the growing trend of preventative healthcare and personalization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Analyst estimates
- Third party market data.
Disclaimers:
This analysis is based on available information and should not be considered investment advice. Actual results may vary. Market share estimates for competitors are from the life insurance sector.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FOXO Technologies Inc.
Exchange NYSE MKT | Headquaters West Palm Beach, FL, United States | ||
IPO Launch date 2021-01-29 | CEO, Interim CFO, Interim Principal Accounting Officer & Director Mr. Seamus Lagan | ||
Sector Healthcare | Industry Health Information Services | Full time employees 102 | Website https://www.foxotechnologies.com |
Full time employees 102 | Website https://www.foxotechnologies.com | ||
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. The company operates through two segments: Healthcare and Labs and Life. The company offers behavioural health; ancillary, including laboratory, radiology, respiratory, and pharmacy; insurance; and other services. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in West Palm Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.